Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390281 | 0.99 | GSK3B (0.33) | GSK3BDYRK1ACNR2 | |
| SCHEMBL7184525 | 0.84 | KDM4E (0.35) | GSK3BDYRK1ACNR2ACSS2MAPK14 | |
| SCHEMBL2389887 | 0.83 | GSK3B (0.40) | GSK3BDYRK1ACNR2P2RX7 | |
| SCHEMBL2390936 | 0.83 | GSK3B (0.40) | GSK3BDYRK1ACNR2P2RX7 | |
| SCHEMBL1986577 | 0.81 | GSK3B (0.43) | GSK3BDYRK1ACNR2ACSS2MAPK14 | |
| SCHEMBL2390274 | 0.76 | RPS6KA3 (0.45) | GSK3BDYRK1A | |
| SCHEMBL2389890 | 0.76 | RPS6KA3 (0.45) | GSK3BDYRK1A | |
| SCHEMBL6428501 | 0.76 | GSK3B (0.41) | GSK3BDYRK1AMAPK14 | |
| SCHEMBL21316476 | 0.76 | NAMPT (0.46) | GSK3BDYRK1ACNR2ACSS2 | |
| SCHEMBL3415059 | 0.76 | GSK3B (0.39) | GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678133-A4 | SEQUENCE SELECTIVE PYRROLE AND IMIDAZOLE POLYAMIDE METALLOCOMPLEXES | UNIV WESTERN SYDNEY (AU) | 2008-06-18 | — | — | EP | disclosed |
| US-20070265240-A1 | Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes | UNIVERSITY OF WESTERN SYDNEY (AU) | 2007-11-15 | — | — | US | disclosed |
| EP-1678133-A1 | SEQUENCE SELECTIVE PYRROLE AND IMIDAZOLE POLYAMIDE METALLOCOMPLEXES | University of Western Sydney (AU) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005033077-A1 | SEQUENCE SELECTIVE PYRROLE AND IMIDAZOLE POLYAMIDE METALLOCOMPLEXES | UNIVERSITY OF WESTERN SYDNEY (AU) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265240-A1 | Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes | POLRMT, MPI, PPIF | GSK3B 4825/4885DYRK1A 2686/4885CNR2 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.